Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-18-293265
Filing Date
2018-10-04
Accepted
2018-10-04 16:01:05
Documents
2
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d616018dsc13ga.htm SC 13G/A 62500
2 EX-99 d616018dex99.htm EX-99 4858
  Complete submission text file 0001193125-18-293265.txt   69143
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

EIN.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Subject) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-80900 | Film No.: 181107949
SIC: 2834 Pharmaceutical Preparations